---
schema_version: "secwatch.filing_event.v1"
accession: "0001826466-22-000034"
form_type: "8-K"
ticker: "NIKA"
cik: "0001145604"
company_name: "NIKA PHARMACEUTICALS, INC"
filed_at: "2022-04-12T23:59:59+00:00"
generated_at: "2026-06-26T07:50:27.969766+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Centennial Growth Equities acquires exclusive rights to TNG and supplements, exits shell status

## Summary
- Acquired 15-year exclusive rights to manufacture and distribute Thymus Nuclear Glycoprotein (TNG) from VITAL FE.
- Also acquired 15-year rights to dietary supplements Palmcarotilen and Fiziolong from MICAR 11.
- Consideration: 8M preferred shares (to Dimitar Savov) for TNG rights; 2M preferred shares for supplement rights.
- Preferred shares granted 1,000 votes each, giving Savov ~10B votes; company no longer a shell company.
- Dimitar Savov is CEO/Director and is the owner of both VITAL (70%) and MICAR (100%).

## SEC filing metadata
- accession: 0001826466-22-000034
- form_type: 8-K
- ticker: NIKA
- cik: 0001145604
- company_name: NIKA PHARMACEUTICALS, INC
- filed_at: 2022-04-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.01, 3.03, 5.06
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1145604/000182646622000034/0001826466-22-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1145604/000182646622000034/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001826466-22-000034
- JSON: https://secwatch.observer/filing/0001826466-22-000034.json
- Plain text: https://secwatch.observer/filing/0001826466-22-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.